Navigation Links
Avanir Pharmaceuticals to Participate in Two Conferences in December
Date:11/26/2013

ALISO VIEJO, Calif., Nov. 26, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in December.

  • Deutsche Bank 2013 BioFEST
    • Presentation date: Tuesday December 3, 2013
    • Presentation time: 8:25 a.m. E.T.
  • 25th Annual Piper Jaffray Health Care Conference
    • Presentation date: Wednesday December 4, 2013
    • Presentation time: 8:30 a.m. E.T.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

A live webcast and 30-day archive of these presentations will be available at http://ir.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com 
+1 (949) 389-670
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
2. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
3. AVANIR Pharmaceuticals To participate in two conferences in March
4. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
8. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 LabStyle Innovations ... Management Solution, today announced it recently closed a ... will be used to support the global rollout ... a mobile, cloud-based, diabetes management solution that includes ... pocket-sized, blood glucose monitoring device, and for working ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... world's most successful food and beverage processors, equipment manufacturers and leaders in the ... inspection and industrial weighing and formulation for manufacturers of bakery and snacks; beverages; ...
(Date:8/30/2015)... August 31, 2015 , ...   für chirurgische   Behandlung     ...   werden für eine   verheerende   Geburtsverletzung behandelt ... und die Anzahl ausgebildeter Chirurgen in Kenia bis 2017 ... heute bekannt, dass  Action on Fistula  seit ihrem Beginn ...
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences , ... International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ... With a focus on evidence-based research and clinical application, the event gathered industry ...
Breaking Biology Technology:LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4
... Trial Meets Primary and Key Secondary Endpoints,NEW YORK, March ... results from the ITI-007 Phase II trial in patients ... ITI-007 significantly and dose-dependently increased slow wave sleep and ... measured by polysomnography (PSG), meeting the prespecified primary and ...
... Key Regulatory MilestoneLONDON, March 10 Monsanto,s historic ... biotechnology has contributed to a 24 percent compound annual ... since 2001. This is one of the key ... will tell investors today as part of a presentation ...
... been known for its world-record-breaking carbon nanotubes. Now ... new uses by spinning carbon nanotubes (CNTs) into ... Breakthroughs Without Broken Threads , Taking ... carbon nanotubes of world-record breaking lengths, researchers Vesselin ...
Cached Biology Technology:Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 2Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 3Spinning carbon nanotubes spawns new wireless applications 2
(Date:8/5/2015)... According to a new market research report, ... (BFSI, Airport, IT & Telecom, Utilities, Education, Defense & ... published by MarketsandMarkets, defines and segments the Physical Identity ... global PIAM Market is estimated to grow from $272.2 ... a CAGR of 14.9 % from 2014 to 2019. ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... the degenerative inflammatory bone disease, may be a sign of ... the Annals of the Rheumatic Diseases. , The authors base ... between 30 and 79. Most of them were female twins. ... to check for signs of osteoarthritis and a blood sample ...
... a chemist by training, first ventured into nerve regeneration ... would have considered him crazy. , His idea was ... by neurotransmitters (chemical messengers) to communicate between the brain ... neurotransmitters into the material used to repair a broken ...
... Manchester researchers are recruiting people with backache caused by ... first ever study to discover if therapeutic ultrasound can ... team at the University's Centre for Rehabilitation Science need ... less than 12 weeks, are not pregnant and have ...
Cached Biology News:Osteoarthritis may be sign of faster 'biological ageing' 2Dopamine used to prompt nerve tissue to regrow 2